openPR Logo
Press release

Acute Lymphocytic Leukemia Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Growth Prospects, ROA, MOA, and Companies by DelveInsight

02-04-2025 05:05 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Acute Lymphocytic Leukemia Clinical Trials

Acute Lymphocytic Leukemia Clinical Trials

(Albany, United States) As per DelveInsight's assessment, globally, Acute Lymphocytic Leukemia pipeline constitutes 150+ key companies continuously working towards developing 160+ Acute Lymphocytic Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Acute Lymphocytic Leukemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Lymphocytic Leukemia Market.

The Acute Lymphocytic Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Acute Lymphocytic Leukemia Pipeline Report:
• Acute Lymphocytic Leukemia Companies across the globe are diligently working toward developing novel Acute Lymphocytic Leukemia treatment therapies with a considerable amount of success over the years.
• Acute Lymphocytic Leukemia companies working in the treatment market are Nanjing Bioheng Biotech, Apamistamab Actinium Pharmaceuticals, Cellectis S.A, Autolus Limited, Takara Bio Inc., AbbVies, Janssen Research & Development, LLC, Jazz Pharmaceuticals, Orca Biosystems, Inc., and others, are developing therapies for the Acute Lymphocytic Leukemia treatment
• Emerging Acute Lymphocytic Leukemia therapies in the different phases of clinical trials are- CTA30X, 131-I, UCART22, AUTO1, TBI-1501, Navitoclax, Daratumumab, CPX-351, Orca-T, and others are expected to have a significant impact on the Acute Lymphocytic Leukemia market in the coming years.
• In December 2024, Groundbreaking results from a major clinical trial, partially supported by the St. Baldrick's Foundation, were revealed today at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, Calif. The Children's Oncology Group (COG) presented transformative findings that are poised to change the standard of care for children with acute lymphoblastic leukemia (ALL). This breakthrough, regarded as one of the most significant advancements in pediatric oncology in decades, marks a milestone made possible by 25 years of contributions to St. Baldrick's head-shaving events, fundraisers, and the generosity of committed donors.
• In November 2024, The U.S. Food and Drug Administration (FDA) has approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This approval marks the first indication for obecabtagene autoleucel, also known as obe-cel. The FDA's decision to approve the chimeric antigen receptor (CAR) T-cell therapy was based on the results of the open-label, multicenter, single-group, Phase 1/2 FELIX clinical trial. The study included patients with ALL who experienced relapse after a remission lasting no longer than 12 months, relapsed or were refractory within 12 months after at least two prior systemic therapies, or had recurrent or refractory disease at least three months following allogeneic stem cell transplantation.
• In July 2024, AstraZeneca, a pharmaceutical company based in the UK, has announced positive results from the Phase III AMPLIFY clinical trial of Calquence (acalabrutinib) for the treatment of chronic lymphocytic leukaemia (CLL). The global, multi-centre, open-label trial evaluated the efficacy and safety of a fixed duration of Calquence (acalabrutinib) in previously untreated adults with CLL. The treatment regimen included Calquence combined with venetoclax and, optionally, obinutuzumab.
• In March 2024, The FDA approved Pfizer's BESPONSA for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell ALL. Before this approval, BESPONSA received priority review and orphan drug designation. Additionally, BESPONSA was approved in 2017 for treating relapsed or refractory B-cell precursor ALL in adult patients.

Acute Lymphocytic Leukemia Overview
An abnormal buildup of white blood cells (leukaemia cells) in the bone marrow causes acute lymphocytic leukaemia (ALL), also known as acute lymphoblastic leukaemia and acute lymphoid leukaemia. The leukaemia cells that leukaemia cannot completely mature replace healthy cells that create functional lymphocytes when ALL advances quickly.

Get a Free Sample PDF Report to know more about Acute Lymphocytic Leukemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Acute Lymphocytic Leukemia Drugs Under Different Phases of Clinical Development Include:
• CTA30X: Nanjing Bioheng Biotech
• 131-I: Apamistamab Actinium Pharmaceuticals
• UCART22: Cellectis S.A
• AUTO1: Autolus Limited
• TBI-1501: Takara Bio Inc.
• Navitoclax: AbbVies
• Daratumumab: Janssen Research & Development, LLC
• CPX-351: Jazz Pharmaceuticals
• Orca-T: Orca Biosystems, Inc.

Acute Lymphocytic Leukemia Route of Administration
Acute Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous.
• Molecule Type

Acute Lymphocytic Leukemia Molecule Type
Acute Lymphocytic Leukemia Products have been categorized under various Molecule types, such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment
• Acute Lymphocytic Leukemia Assessment by Product Type
• Acute Lymphocytic Leukemia By Stage and Product Type
• Acute Lymphocytic Leukemia Assessment by Route of Administration
• Acute Lymphocytic Leukemia By Stage and Route of Administration
• Acute Lymphocytic Leukemia Assessment by Molecule Type
• Acute Lymphocytic Leukemia by Stage and Molecule Type

DelveInsight's Acute Lymphocytic Leukemia Report covers around 160+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Lymphocytic Leukemia product details are provided in the report. Download the Acute Lymphocytic Leukemia pipeline report to learn more about the emerging Acute Lymphocytic Leukemia therapies
https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Acute Lymphocytic Leukemia Therapeutics Market include:
Key companies developing therapies for Acute Lymphocytic Leukemia are - Bristol Myer Squibb Company, Celegene Corporation, Eisai Co Ltd, Erytech Pharma, F. Hoffmann-La Roche Ltd, Genmab A/S, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Sanofi SA, and others.

Acute Lymphocytic Leukemia Pipeline Analysis:
The Acute Lymphocytic Leukemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Lymphocytic Leukemia Treatment.
• Acute Lymphocytic Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Lymphocytic Leukemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Lymphocytic Leukemia drugs and therapies
https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute Lymphocytic Leukemia Market Drivers
• Increase in the prevalence of Acute Lymphocytic Leukemia (ALL), increasing Research and Development activities are some of the important factors that are fueling the Acute Lymphocytic Leukemia Market.

Acute Lymphocytic Leukemia Market Barriers
• However, cost associated with the treatment, side effects associated with the treatment options and other factors are creating obstacles in the Acute Lymphocytic Leukemia Market growth.

Scope of Acute Lymphocytic Leukemia Pipeline Drug Insight
• Coverage: Global
• Key Acute Lymphocytic Leukemia Companies: Nanjing Bioheng Biotech, Apamistamab Actinium Pharmaceuticals, Cellectis S.A, Autolus Limited, Takara Bio Inc., AbbVies, Janssen Research & Development, LLC, Jazz Pharmaceuticals, Orca Biosystems, Inc., and others
• Key Acute Lymphocytic Leukemia Therapies: CTA30X, 131-I, UCART22, AUTO1, TBI-1501, Navitoclax, Daratumumab, CPX-351, Orca-T, and others
• Acute Lymphocytic Leukemia Therapeutic Assessment: Acute Lymphocytic Leukemia current marketed and Acute Lymphocytic Leukemia emerging therapies
• Acute Lymphocytic Leukemia Market Dynamics: Acute Lymphocytic Leukemia market drivers and Acute Lymphocytic Leukemia market barriers

Request for Sample PDF Report for Acute Lymphocytic Leukemia Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Acute Lymphocytic Leukemia Report Introduction
2. Acute Lymphocytic Leukemia Executive Summary
3. Acute Lymphocytic Leukemia Overview
4. Acute Lymphocytic Leukemia- Analytical Perspective In-depth Commercial Assessment
5. Acute Lymphocytic Leukemia Pipeline Therapeutics
6. Acute Lymphocytic Leukemia Late Stage Products (Phase II/III)
7. Acute Lymphocytic Leukemia Mid Stage Products (Phase II)
8. Acute Lymphocytic Leukemia Early Stage Products (Phase I)
9. Acute Lymphocytic Leukemia Preclinical Stage Products
10. Acute Lymphocytic Leukemia Therapeutics Assessment
11. Acute Lymphocytic Leukemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Acute Lymphocytic Leukemia Key Companies
14. Acute Lymphocytic Leukemia Key Products
15. Acute Lymphocytic Leukemia Unmet Needs
16 . Acute Lymphocytic Leukemia Market Drivers and Barriers
17. Acute Lymphocytic Leukemia Future Perspectives and Conclusion
18. Acute Lymphocytic Leukemia Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Lymphocytic Leukemia Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Growth Prospects, ROA, MOA, and Companies by DelveInsight here

News-ID: 3849488 • Views:

More Releases from DelveInsight Business Research

IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA, IND, Treatment market, ROA, Mechanism of Action and Companies by DelveInsight
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Med …
(Albany, USA) DelveInsight's 'IgA Nephropathy Pipeline Insight 2025' report provides comprehensive global coverage of available, marketed, and pipeline IgA nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the IgA nephropathy pipeline domain. IgA nephropathy pipeline report showcase a robust space with 30+ key companies working to develop 30+ pipeline therapies for IgA nephropathy treatment. IgA nephropathy companies
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA, IND, Treatment market, ROA, Mechanism of Action and Companies by DelveInsight
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Clinical Trials and Pipeline 20 …
(Albany, USA) DelveInsight's, "C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the C-MET Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and
Global Kinase Inhibitor in Autoimmune Diseases Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, MOA, ROA, and Companies by DelveInsight
Global Kinase Inhibitor in Autoimmune Diseases Treatment Market 2032: Clinical T …
(Albany, USA) DelveInsight's "Global Kinase Inhibitor in Autoimmune Diseases Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Global Kinase Inhibitor in Autoimmune Diseases, historical and forecasted epidemiology as well as the Global Kinase Inhibitor in Autoimmune Diseases market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Global Kinase Inhibitor in Autoimmune Diseases Market Research
Gastrointestinal Stromal Tumor Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, MOA, ROA, and Companies by DelveInsight
Gastrointestinal Stromal Tumor Treatment Market 2034: Clinical Trials, EMA, PDMA …
DelveInsight's "Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Gastrointestinal Stromal Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastrointestinal Stromal Tumor Market

All 5 Releases


More Releases for Acute

Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape. Request For Sample Report
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595 Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth